News & Media
Get Latest News & Media Releases
US’ Gilead faces competition from Bangladesh’s Beacon pharma
In a classic David Vs Goliath case, the US-based drugmaker Gilead that has made billions of dollars over its blockbuster range of Hepatitis C drugs is facing an unconventional challenger. Beacon Pharma, a little known Bangladeshi drugmaker, has emerged as the David to...
EC Grants Gilead’s Sofosbuvir/Velpatasvir for Chronic Hepatitis C
Gilead Sciences, Inc. (GILD) today announced that the European Commission has granted marketing authorization for Epclusa®, the first pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection. The...
European Commission approves Epclusa for all HCV genotypes
The European Commission approved Gilead Science’s marketing authorization application for Epclusa for the treatment of all chronic hepatitis C genotypes, according to a press release from the manufacturer. Epclusa (sofosbuvir/velpatasvir, Gilead Sciences) is an...
FDA approves Epclusa for treatment of chronic Hepatitis C virus infection
The U.S. Food and Drug Administration approved Epclusa to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis (advanced liver disease). For patients with moderate to severe cirrhosis (decompensated cirrhosis), Epclusa is approved...